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Introduction
Cancer statistics indicate that patient survival has increased over 
the past three decades [1]. This improvement is most frequently 
attributed to the development of  novel therapeutic agentsand 
conduct of  well-conceived clinical trials. Less often (or not 
even) mentioned as a contributor to survivorship is the impact 
supportive care measures may have had in reducing cancer-
related morbidity and possibly, even mortality [2, 3]. However, 
the principal factor associated with these accomplishments may 
ultimately be the improved understanding of  complex genomic, 
molecular, and biochemical pathways that regulate cancer 
processes and treatment-related adverse effects. While the latter 
conclusion may be invariably correct, there is a striking anomaly 
associated with one facet of  supportive care, the prophylaxis of  
chemotherapy-induced emesis (CiE). Frequently considered as 
one of  the most important areas of  advances made in clinical 
oncology, CiE continues to be among the most concerning side 
effects patients associate with cancer therapy [4].
In spite of  the clinical efficacy of  antagonists that block the 
5-hydroxytryptamine 3, (5-HT3) and neurokinin-1 (NK1) receptor 
signaling pathways, classification of  anticancer agents based on 
emetogenic risk level, identification of  patient-related risk factors, 
and promotion of  rational antiemetic guidelines, fulfillment of  
the frequently espoused goal of  preventing emesis, especially 
delayed symptoms, has been far from absolute.
Based on data initially identifying a threshold ratio (i.e., 
>70) of  substance P (sP) to 5-hydroxyindole acetic acid (5-
HIAA)/creatinine (Cr) that appeared to be associated with 
development of  delayed CiE among patients receiving a variety 
of  chemotherapy regimens, we subsequently extended upon our 
previous findings in a uniform cohort of  patients [5, 6]. These 
studies provided the rationale for conducting a validation trial to 
prospectively test the predictive value of  these neurotransmitters 
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in patients undergoing doxorubicin and cyclophosphamide-based 
chemotherapy treatment. The aim of  this paper is to report our 
findings related tothe association between this novel marker and 
risk of  delayed CiE.
Patients and Methods
The clinical research study received full approval of  the 
Institutional Review Board of  West Virginia University. Complete 
details of  the methods associated with this research study have 
been reported previously [5]. As such, only a brief  recapitulation 
of  the study methods is presented here.
Patient Eligibility was Based on the Following Criteria
a. diagnosis of  breast cancer or non-Hodgkin’s lymphoma 
(NHL),
b. treatment with doxorubicin and cyclophosphamide-
containing chemotherapy regimens; 
either “AC” for breast cancer or “CHOP” + rituximab for NHL,
c. performance status: 0 to 1 by Eastern Cooperative 
Oncology Group standards,
d. absence of  baseline vomiting (or nausea), and
e. signed informed consent form.
Study Design
Patients who met the above criteria were eligible to participate in 
this clinical study. None of  the subjects were taking antibiotics or 
opiate analgesics at study entry or during the study-observation 
period. Identification of  these potential confounding factors 
enabled the study to focus on chemotherapy as the principal 
contributing cause of  emesis if  symptoms developed. Blood and 
urine were collected in a single instancebefore chemotherapyin 
order to calculate patient-specific ratios of  the neurotransmitters.
The major reason for inclusion of  patients with two different 
diagnoses was related to a notable discrepancy between the two 
doxorubicin and cyclophosphamide-containing chemotherapy 
regimens. Despite relatively similar doses of  both drugs, only 
the “AC” regimen is considered high-emetic risk level. Even 
though triple drug (i.e., NK1 and 5-HT3 receptor antagonists 
plus dexamethasone) prophylaxis is recommended for patients 
receiving “AC”, the attending oncologist had the option to use 
a two drug regimen (i.e., minus the NK1 receptor antagonist) 
for CiE prophylaxis based on the results of  the pretreatment 
neurotransmitter ratio. Similarly, while routine antiemetic 
prophylaxis for the cohort of  patients with NHL included only 
dual (5-HT3 receptor antagonist and dexamethasone) therapy, 
the attending oncologist had the option to utilize the three-
drug regimen if  the neurotransmitter ratio suggested otherwise.
Of  note, regardless of  whether two or three drugs were used 
antiemetic prophylaxis consisted of  only one dose of  each agent. 
Administration of  chemotherapy began at approximately 1100 
hours in all patients. Specific information related to number (and 
timing) of  emetic episodes (as well as grading of  nausea) was 
obtained from all subjects through completion of  self-assessment 
diaries. Delayed emesis in this study was defined as >2 episodes 
occurring after the first 24 hours (up to 120 hours) following 
initiation of  chemotherapy. Although delayed vomiting may begin 
earlier than this arbitrarily determined time, 24 hours has been 
most frequently used to define the separation between acute and 
delayed symptoms [7].
Neurotransmitter Measurement
Substance P: Approximately 3mLs of  peripheral blood was 
collected in serum separator tubes. In order to stabilize the 
protein, 500 KIU/mL of  aprotonin was added to the blood 
samples within five minutes of  collection. The blood was allowed 
to clot, then centrifuged at 1000 x G for 10 minutes at 4C. Serum 
was removed and diluted 1:2 with the kit assay buffer. Substance 
P was measured using a commercially available immunoassay 
(Substance P Assay, ParameterTM, Catalog Number KGE007, R 
& D Systems, Inc. Minneapolis, MN). The assay is based on the 
competitive binding technique in which SP present in a sample 
competes with a fixed amount of  horseradish peroxidase-labeled 
sP for sites on a mouse monoclonal antibody. In brief, during 
incubation the monoclonal antibody becomes bound to the goat 
anti-mouse antibody coated onto the microplate. Following a 
wash to remove excess conjugate and unbound sample, a substrate 
solution is added to the wells to determine the bound enzyme 
activity. The color development is stopped and the absorbance 
is read at 450 nm (uQuantTM, Bio-Tek Instruments, Winooski, 
VT). The intensity of  the color is inversely proportional to the 
concentration of  SP in the sample. All samples were tested in 
duplicate as recommended by the manufacturer.
Serotonin: Because 5-HIAA is the major serotonin metabolite, 
the breakdown product was determined to be a reliable surrogate 
of  the neurotransmitter. After adjusting the pH of  the urine 
specimen with hydrochloric acid, the appointed metabolite and 
creatinine were quantitatively assayed by high-performance liquid 
chromatography (HPLC).
Data analysis
Absolute values of  sP and 5-HIAA/Cr were determined for 
each patient. As stated in our previous reports, the possibility 
of  neurotransmitter overlap (i.e., involvement of  both 
neurotransmitters) in the genesis of  delayed emesis provided a 
strong rationale for evaluating values of  both neurotransmitters 
simultaneously. As such, the ratio of  sP to 5-HIAA/Cr was 
selected because clinical trials assessing the efficacy of  5-HT3 and 
NK1 receptor antagonists suggested sP had a relatively greater 
role in the delayed phase compared to serotonin [8, 9].
sP to 5-HIAA/Cr ratios were arranged numerically, highest 
to lowest (Table 1); corresponding information related to 
development of  delayed emesis is also noted for each of  the 
ratio values. Between-emesis group variance (log[mean]) for each 
of  the pre-specified markers of  patients who did (+) or did not 
(-) develop delayed emesis was analyzed by One way ANOVA, 
JMPTM, Version 12.0.1, SAS Institute, Cary, NC.
Results
Between March 2014 and February 2016, 36 patients provided 
signed informed consent to participate in the study; demographics 
of  the study population are shown in Table 2. Among the entire 
cohort of  subjects enrolled in the study, delayed emesis developed 
in only five subjects, all of  who received triple-drug antiemetic 
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Table 1. Marker Ratios with Corresponding Emetic Outcomes.
Ratio Delayed CiE (Y/N)
167 Y
163 N
143 N
121 N
120 N
103 Y
99 N
95 Y
91 N
84 N
77 N
68 N
60 N
59 N
53 N
46 N
40 N
34 N
33 N
32 N
28 N
28 N
22 N
18 N
17 Y
17 Y
15 N
12 N
12 N
11 N
10 N
10 N
9 N
8 N
5 N
3 N
Table 2. Demographics of  Study Population.
Age in years, mean (range), 58 (36-81)                    
Gender (number patients)
    Male (9)
   Female (27)
Tumor type
   Breast (25)
   NHL (11)
Performance status, ECOG, (number patients)
   0 (35)
   1 (1)
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prophylaxis. Three of  these five patients had sP to 5-HIAA/
Cr ratio of  >70. Mean values of  the pretreatment variables for 
patients with (+) and without (-) emesis were 74.2 and 48.8, 
respectively. Non-parametric analysis indicated the between-
emesis group variance was not significantly different, p=0.154. 
None of  the patients with non-Hodgkin’s lymphoma developed 
delayed CiE. Although the primary endpoint was delayed emesis, 
moderate to severe nausea was reported in 21 patients, all with 
diagnoses of  breast cancer; two subjects (both males) with NHL 
reported mild nausea only.
Discussion
Results of  clinical trials suggest that serotonin and substance P 
play prominent roles in acute and delayed CiE, respectively [8-10]. 
These findings are potentially important especially with regard to 
the use of  NK1 receptor antagonists (RA). Recently, post hoc 
analysis of  data indicated the risk of  developing delayed emesis 
was associated with a marker, the ratio of  sP to 5-HIAA/Cr >70 
[5, 6]. In order to prospectively determine the predictive value 
of  this marker, an IRB-approved clinical trial was conducted 
involving subjects who may receive the NK1RA, aprepitant, as 
antiemetic prophylaxis.
A critical analysis of  the data in patients who were treated with two 
doxorubicin and cyclophosphamide-containing chemotherapy 
regimens did not validate the premise that the pretreatment ratio 
of  sP to 5-HIAA/Cr >70 was associated with risk of  developing 
delayed CiE. However, embedded within the data are two issues 
of  note. One relates to the small number of  subjects (i.e. 11) with 
ratios greater than 70. Of  the nine patients with breast cancer 
who received the three-drug prophylaxis, three developed delayed 
emesis. That six of  the nine patients had no emetic episodes is 
consistent with previous reports of  the overall efficacy associated 
with addition of  an NK1 RA to the antiemetic regimen [11, 12]. 
The second relates to the larger cohort of  subjects with ratios 
<70. Even though the predicted incidence of  delayed emesis 
in this set of  patients would be lower, the use of  the NK1 RA 
in 16 subjects treated with “AC” may have masked what would 
have been a higher rate of  emetic events had the agent not been 
used (as was recommended by the study investigators) based on 
the ratio alone. Using the same rationale described previously in 
subjects with ratios >70 and based on the high emetogenic risk 
level associated with this chemotherapy regimen, it was estimated 
that no more than 11 patients with breast cancer would have truly 
benefitted from the addition of  the NK1RA suggesting that the 
other five subjects would not have required the same drug for 
a comparable outcome. Indeed, this belief  is supported by two 
clinical trials in patients with breast cancer undergoing “AC” 
treatment [13, 14]. With this supposition, a significant probability 
of  developing delayed emesis for those above the threshold ratio 
(compared to subjects with ratios below the cutoff) was found by 
Fisher’s Exact Test, p=0.0372.
Perhaps the most important piece of  information gained from 
this study was an explanation why the CHOP regimen is not also 
classified as high emetic risk. Despite relatively similar doses of  
doxorubicin and cyclophosphamide and foregoing use of  an 
NK1 RA, none of  the subjects with NHL developed delayed 
emetic symptoms; and only two (male) patients reported nausea, 
which was rated as mild in both cases. These outcomes strongly 
suggest prophylaxis for delayed-phase symptoms was partially (or 
even in large part) attributable to multi-day prednisone therapy 
in the CHOP regimen, the dosage of  which was approximately 
two-fold higher than the dose of  dexamethasone used in most 
clinical trials [11, 14].
The relevance of  these findings in daily clinical practice could 
be minimized by a number of  salient issues. First, and foremost, 
the results of  the ratio’s predictive value did not reach statistical 
significance. However, inherent also in the data was a clear trend 
for developing delayed emesis among subjects with ratios >70 
compared to those with ratios less than that value, 27% and 
8%, respectively. Second, the only statistically significant finding 
resulted from data speculated upon. Nonetheless, construction 
of  the two groups (i.e., with and without emesis) was based on 
insight from larger clinical studies which evaluated two-and-
three-drug prophylaxis in similar patients [11, 12]. Third, there 
is a notable imbalance in numbers of  patients with breast cancer 
compared to NHL. However, it was reassuring that the clinical 
efficacy of  adding an NK1 RA to patients treated with “AC” 
and a high ratio was consistent with results from previously 
published studies [11, 12]. Furthermore, the finding that only 
two of  16 patients with breast cancer and ratios below 70 had 
delayed emesis suggests that a smaller, yet significant, subset of  
patients undergoing “AC” treatment would do well with only 
5-HT3 RA and dexamethasone prophylaxis. Fourth, consistent 
adherence to antiemetic guidelines precluded the use the baseline 
ratios in a truly prospective manner. Nevertheless, the findings re-
confirm the efficacy of  glucocorticoids as prophylaxis for delayed 
emesis and support the conclusion that the precise biochemical 
mechanisms for delayed symptom development is not exclusively 
mediated by substance P [15].
Conclusion
Current recommendations for prevention of  delayed CiE are 
based almost exclusively on chemotherapy emetic-risk level. 
Arguably, “AC”, which is classified as high-emetic risk, is one 
of  the few treatment regimens that consider both gender and 
clinical experience. That similar dosages of  doxorubicin and 
cyclophosphamide in the “CHOP” regimen do not garner the 
same emetic risk classification partially supports the previous 
statement. Furthermore, clinical experience with the two drug 
combination (i.e.,”A” and “C”) in patients with NHL appears to 
justify a moderate-risk classification, one that is likely attributable 
to multi-day doses of  high-dose glucocorticoid.
These data represent the final phase of  our study related toa novel 
marker associated with risk of  delayed emetic symptoms. We were 
not able to prospectively validate the marker’s predictive value, 
in part, because the relatively small sample size may have been 
insufficient to show statistical significance.
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